CA 15-3 (breast cancer)
CA 15-3 is a tumour marker used mainly to monitor breast cancer. It is used to follow the course of the disease, to detect recurrence and to assess how well treatment is working.
Preparation and sampling
- Preparation
- Guide to preparing for tests
- Sample
- Blood
- Results available in
- 1 working day
- Where it is done
- All laboratories and map
Description
About the test
CA 15-3 (cancer antigen 15-3) is a glycoprotein, part of the MUC1 molecule, found on the surface of glandular epithelial cells, including breast cells. Some breast cancer cells, especially in advanced (metastatic) disease, produce it and release it into the blood in larger amounts.
Tumour markers are substances produced by tumour cells or by the body in response to a tumour. Healthy cells and benign tumour cells can also produce them in smaller amounts, so a raised value on its own does not mean that cancer is present.
CA 15-3 is used mainly in people who have already been diagnosed with breast cancer: to follow the course of the disease and the response to treatment and to detect recurrence, together with clinical examination and imaging.
CA 15-3 is not a screening or diagnostic test for breast cancer: in the early stages levels are often normal, and raised levels also occur in other conditions. Breast examination, ultrasound and mammography are used for the early detection of breast cancer.
For monitoring, it is important that the test is done with the same method, ideally in the same laboratory, because results obtained with different methods are not directly comparable.
When it is recommended
- Before starting treatment for breast cancer, as a baseline for later monitoring;
- Monitoring the response to treatment (chemotherapy, hormonal or targeted therapy), especially in metastatic disease;
- Follow-up after completed treatment, to detect recurrence, as recommended by the oncologist;
- Assessing the course of the disease, alongside clinical examination and imaging.
Preparation
- The test itself needs no special preparation or fasting.
- When the test is used for monitoring, give your samples in the same laboratory if possible, at the intervals set by your doctor.
- Tell your doctor about the treatment you are receiving and about any known liver disease.
- General laboratory rules for blood tests: for most tests, blood is taken in the morning, between 7 and 10 a.m., after 12 hours of fasting (you may drink water as usual). If you take medicines, blood is taken before your morning dose, unless your doctor advises otherwise. Do not take vitamin supplements on the day before the blood test, and avoid strenuous physical exercise for 2 days beforehand.
Sample
Venous blood.
Reference values
For most methods, the upper limit of the reference range in healthy people is approximately 25–31 U/mL.
When monitoring the disease, the change in values over time matters more than a single result.
Reference values depend on the method and the laboratory; the values printed on your report apply to your result.
Interpreting the results
Raised levels in people with breast cancer may indicate active or more extensive disease. A rise during monitoring may point to progression or recurrence, while a fall suggests a good response to treatment. In the first weeks of a new course of chemotherapy a temporary rise is possible and does not necessarily mean worsening.
Raised CA 15-3 levels can also occur in:
- other cancers, such as cancer of the ovary, lung, pancreas, liver, stomach or bowel;
- liver disease (chronic hepatitis, cirrhosis);
- benign breast disease;
- some chronic inflammatory and autoimmune diseases;
- some lung diseases.
Normal levels do not rule out breast cancer, especially in its early stages, or its recurrence.
Your doctor interprets the result together with your symptoms and other findings.
What can affect the result
- Different methods and laboratories – results are not directly comparable;
- Liver disease;
- Benign breast disease;
- The start of chemotherapy (a temporary rise is possible);
- Other cancers or chronic inflammatory diseases.
Related tests
- CEA (carcinoembryonic antigen) – often monitored together with CA 15-3;
- Breast ultrasound and mammography – the main methods for detecting changes in the breast;
- Imaging (abdominal ultrasound, CT, MRI, bone scan) – to assess the extent of the disease, as recommended by the oncologist;
- ALT, AST, GGT and alkaline phosphatase – to assess liver function and possible involvement of the liver or bones;
- Full blood count – general assessment and monitoring during treatment.
Frequently ordered together
How to order tests online?
Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.
Payment method:
- Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
- At the laboratory – order your tests online and pay for them when you come to the laboratory.
After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.